Childhood Malignant Neoplasm
Conditions
Brief summary
This research trial studies neuropsychological (learning, remembering or thinking) and behavioral outcomes in children and adolescents with cancer by collecting information over time from a series of tests.
Detailed description
PRIMARY OBJECTIVES: I. To institute procedures to ensure a consistent, streamlined, and efficient administration of the neuropsychological/behavioral tests in a cooperative group setting in order to maximize compliance with a standardized assessment battery conducted at 3 standardized time points. OUTLINE: Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.
Interventions
PROCEDURECognitive Assessment
Complete COG Standard Neuropsychological and Behavioral Battery
OTHERQuality-of-Life Assessment
Ancillary studies
Sponsors
Children's Oncology Group
National Cancer Institute (NCI)
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Months to No maximum
Healthy volunteers
No
Inclusion criteria
* The patient must be currently be enrolled or plan to be enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning * The patient must have receptive and expressive language skills in English, French, or Spanish; if a patient meets these criteria but the parent/guardian speaks a language other than English, French, or Spanish, the patient may still be enrolled and tested, and the parent-report measures should be omitted * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion criteria
* Patients with a history of moderate to profound intellectual disability (i.e. intelligence quotient \[IQ\] =\< 55) are not eligible for enrollment; PLEASE NOTE: Children with a prior history of attention deficit hyperactivity disorder (ADHD) or a specific learning disability (e.g., dyslexia) are eligible for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compliance rate for completion of neuropsychological and behavioral battery | Up to 72 months post-diagnosis |
Countries
Australia, Canada, New Zealand, Puerto Rico, United States
Contacts
PRINCIPAL_INVESTIGATORLeanne M Embry
Children's Oncology Group
Outcome results
None listed